Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) FCF Margin (2019 - 2025)

BridgeBio Pharma's FCF Margin history spans 7 years, with the latest figure at 36.62% for Q4 2025.

  • For Q4 2025, FCF Margin rose 329533.0% year-over-year to 36.62%; the TTM value through Dec 2025 reached 89.03%, up 14605.0%, while the annual FY2025 figure was 89.03%, 14605.0% up from the prior year.
  • FCF Margin for Q4 2025 was 36.62% at BridgeBio Pharma, up from 91.66% in the prior quarter.
  • Across five years, FCF Margin topped out at 14909.4% in Q4 2021 and bottomed at 40213.61% in Q3 2022.
  • The 5-year median for FCF Margin is 3449.96% (2023), against an average of 5584.57%.
  • The largest YoY upside for FCF Margin was 9031104bps in 2021 against a maximum downside of -3522433bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 14909.4% in 2021, then tumbled by -132bps to 4773.8% in 2022, then crashed by -49bps to 7108.77% in 2023, then soared by 53bps to 3331.94% in 2024, then surged by 99bps to 36.62% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's FCF Margin are 36.62% (Q4 2025), 91.66% (Q3 2025), and 72.67% (Q2 2025).